Biohaven Pharmaceutical
$91.369876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$91.36
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
+$1.74 (+1.94%) Today
$0.00 (0.00%) As of 5:00 PM EST after-hours
Why Robinhood?
You can buy or sell BHVN and other stocks, options, and ETFs commission-free!
About BHVN
Biohaven Pharmaceutical Holding Company Ltd., also called Biohaven Pharmaceutical, is a clinical-stage biopharmaceutical company, which engages in the research and development of late-stage product candidates targeting neurological diseases, including rare disorders. It focuses on a pipeline of product candidates that represent mechanistic platforms, calcitonin gene-related peptide receptor antagonists, and glutamate modulators. The company was founded in September 2013 and is headquartered in New Haven, CT. The listed name for BHVN is Biohaven Pharmaceutical Holding Company Ltd.
CEO
Vlad Coric
Employees
647
Headquarters
New Haven, Connecticut
Founded
2013
Market Cap
5.48B
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
886.00K
High Today
$92.33
Low Today
$90.42
Open Price
$90.67
Volume
219.21K
52 Week High
$100.77
52 Week Low
$26.56
Collections
Analyst Ratings
90%
of 10 ratings
Buy
90%
Hold
10%
Sell
0%
BHVN Earnings
-$2.89
-$1.93
-$0.96
$0.00
Q1 FY19
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
— per share
Actual
Expected Feb 25, Pre-Market